| Aflatoxin, Polycyclic Aromatic Hydrocarbons, Heavy metals and DNA Methylation in Hepatocellular Carcinoma |
HuiChen Wu |
Columbia University |
PLCO |
Sep 7, 2022 |
2022-0003 |
| The timing between the diagnosis and the end of the last treatment in the cancer continuum in patients with lung cancer by TNM stages; and the impact of delays in the final survival of the patients, in PLCO, In the period available in the data set. |
Percy Guzman |
NCI |
PLCO |
Sep 6, 2022 |
PLCO-1036 |
| Post-diagnosis exercise and mortality risk in cancer survivors |
Jessica Gorzelitz |
University of Iowa |
PLCO |
Sep 6, 2022 |
PLCO-1032 |
| Prostate specific antigen volatility and the diagnosis of clinically significant prostate cancer |
John Leppert |
Stanford University |
PLCO |
Aug 29, 2022 |
PLCO-1034 |
| Metabolic health phenotypes, accelerated biological aging and cancer risk. |
Prasoona Karra |
Geisel School of Medicine at Dartmouth College |
PLCO |
Aug 29, 2022 |
PLCO-1028 |
| Use of PLCO data to evaluate the performance of cancer risk models |
Thomas Ahearn |
Division of Cancer Genetics and Epidemiology, NCI |
PLCO |
Aug 22, 2022 |
PLCO-1025 |
| Data Analysis of Male Breast Cancer |
Vaidehi Gajera |
Western Sydney University |
PLCO |
Aug 22, 2022 |
PLCO-1029 |
| Identifying risk factors for depression and the role of depression in cancer |
Lei Zhang |
Uniformed Services University |
PLCO |
Aug 22, 2022 |
PLCO-1027 |
| Prediction of Absolute Risk of Ovarian and Endometrial Cancer |
Sokbom Kang |
National Cancer Center, Korea |
PLCO |
Aug 22, 2022 |
PLCO-1023 |
| Determination of the association between BDNF, a potential biomarker, and depression in patients with cancer |
Lei Zhang |
Uniformed Services University |
PLCO |
Aug 22, 2022 |
PLCO-1021 |
| Fatty acids intake with emphasis on trans fatty acids and risks of Breast cancer and Colorectal Cancer |
Paolo Boffetta |
The Department of Medical and Surgical Sciences (DIMEC), the University of Bologna |
PLCO |
Aug 22, 2022 |
PLCO-1018 |
| Bladder Cancer Data Visualization |
OMAR GALDAMEZ CRUZ |
CENTRO DE DISEÑO Y COMUNICACION, S.C. |
PLCO |
Aug 2, 2022 |
PLCO-1011 |
| Prognostic factors in HER2-positive breast cancer |
Reem Chamseddine |
Weill Cornell Medicine-Qatar |
PLCO |
Aug 2, 2022 |
PLCO-1014 |
| Clarifying the relationship between body mass index and lung cancer using causal inference methods |
Rajat Das Gupta |
University of South Carolina |
PLCO |
Aug 2, 2022 |
PLCO-1010 |
| A Phase II extension of the use of cg05575921 Methylation to predict risk for lung cancer |
Robert Philibert |
Behavioral Diagnostics |
PLCO |
Aug 1, 2022 |
2022-0014 |
| Characterization of serum immuno-oncology biomarker levels in PLCO participants with mosaic chromosomal alterations |
Mitchell Machiela |
National Cancer Institute |
PLCO |
Aug 1, 2022 |
2022-0022 |
| Survival Analysis and the Effect of Censoring for Lung Cancer |
Azar Shahraz |
AstraZeneca |
PLCO |
Jul 22, 2022 |
PLCO-991 |
| Identification of Risk Factors and Patient Populations at Risk for Developing Cancer of the Head and Neck |
Jay Piccirillo |
Washington University School of Medicine in St. Louis |
PLCO |
Jul 14, 2022 |
PLCO-1003 |
| Screening for ovarian cancer in women with a personal or family history of breast or ovarian cancer |
Nathan Bromham |
National Institute for Health and Care Excellence |
PLCO |
Jul 12, 2022 |
PLCO-1002 |
| Developing a multi-marker diagnostic test with predictive model enhancements for early-stage (Stage-1) Ovarian cancer |
Srinagesh Satyanarayana |
Kaya17 |
PLCO |
Jul 1, 2022 |
PLCO-1000 |
